Use of Verciguat in the Treatment of Heart Failure

Heart failure remains a major challenge in contemporary cardiology, characterized by high morbidity, frequent hospitalizations, and an unfavorable prognosis despite substantial advances in guideline-directed therapy. Although modern multidrug treatment has improved clinical outcomes, a considerable proportion of patients continue to experience disease progression and recurrent exacerbations, particularly in high-risk populations. Vericiguat is a novel oral agent used in the treatment of heart failure and represents an adjunct to standard therapy in selected patients. To date, clinical studies have evaluated the efficacy and safety of vericiguat in patients with both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Available evidence suggests that the clinical effects of vericiguat vary depending on the heart failure phenotype and the clinical context, including disease stability and the risk of further deterioration. This paper provides a comprehensive review of current data on the use of vericiguat across different heart failure phenotypes, with particular emphasis on clinical trial outcomes, therapeutic efficacy, and safety profile. The limitations of existing evidence are discussed, along with the potential role of vericiguat within contemporary treatment strategies. Overall, current findings indicate that vericiguat should not be regarded as a universal therapy for all patients with heart failure, but rather as a complementary treatment option for carefully selected individuals, in whom additional therapeutic strategies may be required.